Stay updated on CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial

Sign up to get notified when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.0, replacing Revision: v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-18T18:02:46.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. This appears to be a system-level update with no visible changes to the study details on the page.
    Difference
    0.0%
    Check dated 2026-03-11T16:56:06.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    An administrative revision tag (v3.4.2) was added and previously displayed notices about government funding and operating status were removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-11T02:04:17.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Added a government funding lapse notice banner. Updated the page revision tag from v3.4.0 to v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-03T23:29:42.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    A glossary display option has been added. Labels related to QC status and FEAR Act data were capitalized (Last Update Submitted that Met QC Criteria; No FEAR Act Data) and the revision version updated to v3.4.0.
    Difference
    0.2%
    Check dated 2026-01-27T21:52:36.000Z thumbnail image
  8. Check
    101 days ago
    Change Detected
    Summary
    Added a Locations section listing new sites in Arizona, California, Connecticut, Florida, Maryland, Nebraska, New York, Ohio, Pennsylvania, and Tennessee. Removed the individual state location sections and the HHS Vulnerability Disclosure link; updated the revision from v3.3.2 to v3.3.3.
    Difference
    0.9%
    Check dated 2025-12-23T08:43:18.000Z thumbnail image

Stay in the know with updates to CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.